What is the primary impact of these agreements on Regeneron's business?

The primary impact is the resolution of all outstanding patent litigation with Genentech concerning EYLEA and ZALTRAP, providing legal certainty and securing worldwide non-exclusive licenses for these key products. This allows Regeneron and its partners to continue commercializing EYLEA and ZALTRAP globally without the threat of ongoing legal disputes over the licensed patents.

What are the financial implications of these settlements for Regeneron?

Regeneron will make payments to Genentech based on the sales of EYLEA and ZALTRAP. For EYLEA, this includes royalties on U.S. sales and ex-U.S. sales manufactured in the U.S. through May 7, 2016, with rates varying based on cumulative sales thresholds. For ZALTRAP, similar payment obligations exist for Regeneron and Sanofi, tied to sales milestones and royalties up to May 7, 2016. Bayer HealthCare will also share in some of these EYLEA-related payments.

How do these agreements affect the commercialization of EYLEA and ZALTRAP outside the United States?

The agreements grant Regeneron (for EYLEA in the ocular field) and Regeneron/Sanofi (for ZALTRAP in non-ocular fields) worldwide non-exclusive licenses. This is critical for EYLEA, as it clarifies Regeneron's and Bayer's rights globally. For ZALTRAP, it solidifies the global rights for Regeneron and Sanofi. The financial terms related to ex-U.S. sales are structured to account for these global commercialization efforts.

Are there any ongoing risks or uncertainties associated with these settlements?

While the litigation is resolved, the settlements involve ongoing payment obligations tied to future sales performance. Regeneron faces the financial commitment of royalties and milestone payments as sales reach certain thresholds. The company's profitability will be impacted by these payments, especially as sales grow. The 'non-exclusive' nature of the licenses means other parties might hold rights to related patents not covered by these agreements.

REGN 8-K: Material Agreements

Summary

Regeneron Pharmaceuticals, Inc. (REGN) has entered into significant settlement agreements with Genentech, Inc., resolving all outstanding litigation concerning EYLEA® (aflibercept) Injection and ZALTRAP® (ziv-aflibercept) Injection. These agreements include worldwide non-exclusive licenses for key patents, particularly the Davis-Smyth patents, which are crucial for the development and sale of both flagship products. For EYLEA, Regeneron has secured a worldwide license in the ocular field. This settlement involves ongoing payments to Genentech based on U.S. sales and ex-U.S. sales manufactured in the U.S., with specific milestone and royalty rates outlined until May 7, 2016. Similarly, for ZALTRAP, Regeneron and its partner Sanofi have obtained a worldwide license for all indications outside the ocular field, also with associated payment obligations to Genentech tied to sales milestones and royalties until May 7, 2016.

Key Highlights

1Resolution of all pending patent litigation with Genentech concerning EYLEA and ZALTRAP.
2Regeneron secures a worldwide non-exclusive license to key patents (Davis-Smyth) for EYLEA in the ocular field.
3Regeneron and Sanofi secure a worldwide non-exclusive license to key patents (Davis-Smyth) for ZALTRAP in all non-ocular indications.
4EYLEA settlement involves payments to Genentech based on U.S. sales and ex-U.S. sales manufactured in the U.S., with royalty rates of 4.75% (between $400M-$3B) and 5.5% (over $3B) until May 7, 2016.
5ZALTRAP settlement involves payments to Genentech by Regeneron and Sanofi based on U.S. sales and ex-U.S. sales manufactured in the U.S., with royalty rates of 4.5% (between $400M-$1B) and 6.5% (over $1B) until May 7, 2016.
6The agreements include dismissal of current patent litigation and covenants not to sue related to specific Genentech patents.
7Bayer HealthCare will share in EYLEA-related payments to Genentech based on its proportion of ex-U.S. sales.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Material Agreement (May 20, 2013)

Summary

Key Highlights

Frequently Asked Questions